Clinical Trials in Ancona, AN

14 recruiting

Showing 112 of 12 trials

Recruiting
Phase 3

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Hidradenitis Suppurativa
Novartis Pharmaceuticals250 enrolled8 locationsNCT07543419
Recruiting
Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled92 locationsNCT06813911
Recruiting
Phase 2

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Aortic Stenosis
Novartis Pharmaceuticals502 enrolled139 locationsNCT05646381
Recruiting
Phase 2

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals200 enrolled127 locationsNCT06470048
Recruiting
Phase 3

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Hidradenitis Suppurativa
Novartis Pharmaceuticals555 enrolled145 locationsNCT06799000
Recruiting
Phase 2

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled93 locationsNCT06581198
Recruiting
Phase 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Scleroderma, Diffuse
Novartis Pharmaceuticals96 enrolled80 locationsNCT06655896
Recruiting
Phase 2

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Novartis Pharmaceuticals224 enrolled99 locationsNCT06947993
Recruiting

Italian Network MDS Registry

Myelodysplastic-Myeloproliferative Diseases
Fondazione Italiana Sindromi Mielodisplastiche-ETS10,000 enrolled20 locationsNCT02808858
Recruiting

BRING-UP 3 Heart Failure

Heart Failure
Heart Care Foundation10,000 enrolled187 locationsNCT06279988
Recruiting

BRING-UP Prevention

Peripheral Arterial DiseaseCerebrovascular DisordersIschemic Heart Disease
Heart Care Foundation6,000 enrolled196 locationsNCT06275113